Identification of host and viral factors involved in a dissimilar resolution of a hepatitis C virus infection

Liver International

Volumn 34, Issue 6, 2014, Pages 896-906

  Cubero, Maria ^a,h   Gregori, Josep ^a,h   Esteban, Juan I ^a,b,c   García Cehic, Damir ^a,b   Bes, Marta ^b,d   Perales, Celia ^b,e   Domingo, Esteban ^b,e   Rodríguez Frías, Francisco ^b,c,f   Sauleda, Silvia ^b,d   Casillas, Rosario ^a,f   Sanchez, Alex ^g   Ortega, Israel ^g   Esteban, Rafael ^a,b,c   Guardia, Jaume ^a,b,c   Quer, Josep ^a,b,c  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d INSTITUT CATALÀ DE LA SALUT   (Spain)

^e CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOA   (Spain)

^f Microbiology Unit   (Spain)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^h Roche Diagnostics SL Diabetes Care   (Spain)

Author keywords

Chronicity; HCV; NS3; Quasispecies; Resolution; UDPS

Indexed keywords

ALANINE AMINOTRANSFERASE; CD4 ANTIGEN; PEGINTERFERON; RIBAVIRIN; ANTIVIRUS AGENT; NS3 PROTEIN, HEPATITIS C VIRUS; VIRUS PROTEIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD DONOR; CASE REPORT; CHRONIC ACTIVE HEPATITIS; CHRONICITY; DISEASE TRANSMISSION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HOST; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; LIVER BIOPSY; MALE; NUCLEOTIDE SEQUENCE; PROSPECTIVE STUDY; PYROSEQUENCING; RECIPIENT; SEROCONVERSION; SEXUAL INTERCOURSE; SEXUAL TRANSMISSION; SEXUALLY TRANSMITTED DISEASE; TREATMENT DURATION; VIRAL CLEARANCE; VIRUS LOAD; COMPLICATION; DRUG EFFECTS; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HOST PATHOGEN INTERACTION; IMMUNOLOGY; PATHOGENICITY; PHENOTYPE; REMISSION; SEXUALITY; SEXUALLY TRANSMITTED DISEASES, VIRAL; SUBSTANCE ABUSE; TIME; TRANSMISSION; TREATMENT OUTCOME; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HOST-PATHOGEN INTERACTIONS; HUMANS; MALE; PHENOTYPE; REMISSION INDUCTION; SEXUAL PARTNERS; SEXUALLY TRANSMITTED DISEASES, VIRAL; SUBSTANCE ABUSE, INTRAVENOUS; TIME FACTORS; TREATMENT OUTCOME; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84902535718     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12362     Document Type: Article

References (48)

1. National Institutes of Health Consensus Development Conference Statement. Management of hepatitis C: 2002-June 10-12, 2002. Hepatology 2002; 36: S3-20.
2. Quer J, Esteban JI. Epidemiology. In: Zuckerman AJ, Thomas HC, eds. Viral Hepatitis. London: Churchill Livingstone, 1998; 271-83.
3. Suppiah V, Gaudieri S, Armstrong NJ, et al. IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study. PLoS Med 2011; 8: e1001092.
4. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
5. Afdhal NH, McHutchison JG, Zeuzem S, et al. Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology 2011; 53: 336-45.
6. Sugimoto K, Ikeda F, Stadanlick J, et al. Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. Hepatology 2003; 38: 1437-48.
7. Diepolder HM, Zachoval R, Hoffmann RM, et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995; 346: 1006-7.
8. Gerlach JT, Diepolder HM, Jung MC, et al. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology 1999; 117: 933-41.
9. Lauer GM, Barnes E, Lucas M, et al. High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology 2004; 127: 924-36.
10. Wertheimer AM, Miner C, Lewinsohn DM, et al. Novel CD4 + and CD8 + T-cell determinants within the NS3 protein in subjects with spontaneously resolved HCV infection. Hepatology 2003; 37: 577-89.
11. Quer J, Murillo P, Esteban JI, et al. Sexual transmission of hepatitis C virus from a patient with chronic disease to his sex partner after removal of an intrauterine device. Sex Transm Dis 2003; 30: 470-1.
12. Bes M, Sauleda S, Casamitjana N, et al. Reversal of nonstructural protein 3-specific CD4(+) T cell dysfunction in patients with persistent hepatitis C virus infection. J Viral Hepat 2012; 19: 283-94.
13. Homs M, Buti M, Quer J, et al. Ultra-deep pyrosequencing analysis of the hepatitis B virus preCore region and main catalytic motif of the viral polymerase in the same viral genome. Nucleic Acids Res 2011; 39: 8457-71.
14. Campbell PJ, Pleasance ED, Stephens PJ, et al. Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing. Proc Natl Acad Sci U S A 2008; 105: 13081-6.
15. Huse SM, Huber JA, Morrison HG, Sogin ML, Welch DM. Accuracy and quality of massively parallel DNA pyrosequencing. Genome Biol 2007; 8: R143.
16. Zagordi O, Klein R, Daumer M, Beerenwinkel N. Error correction of next-generation sequencing data and reliable estimation of HIV quasispecies. Nucleic Acids Res 2010; 38: 7400-9.
17. Bhattacharyya A. On a measure of divergence between two statistical populations defined by their probability distributions. Bulletin of the Calcutta Mathematical Society 1943; 35: 99-109.
18. Bengsch B, Thimme R, Blum HE. Role of host genetic factors in the outcome of hepatitis C virus infection. Viruses 2009; 1: 104-25.
19. Farci P, Shimoda A, Coiana A, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies Science 2000; 288: 339-44.
20. Quer J, Esteban JI, Cos J, et al. Effect of bottlenecking on evolution of the nonstructural protein 3 gene of hepatitis C virus during sexually transmitted acute resolving infection. J Virol 2005; 79: 15131-41.
21. McKiernan SM, Hagan R, Curry M, et al. Distinct MHC class I and II alleles are associated with hepatitis C viral clearance, originating from a single source. Hepatology 2004; 40: 108-14.
22. Thio CL, Gao X, Goedert JJ, et al. HLA-Cw*04 and hepatitis C virus persistence. J Virol 2002; 76: 4792-7.
23. Asahina Y, Tsuchiya K, Muraoka M, et al. Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response. Hepatology 2012; 55: 20-9.
24. Domingo E, Sheldon J, Perales C. Viral quasispecies evolution. Microbiol Mol Biol Rev 2012; 76: 159-216.
25. WHO Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999; 6: 35-47.
26. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
27. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
28. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-93.
29. Rumi MG, Aghemo A, Prati GM, et al. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology 2010; 138: 108-15.
30. Puig-Basagoiti F, Forns X, Furcic I, et al. Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C. J Gen Virol 2005; 86: 1067-75.
31. Aparicio E, Franco S, Parera M, et al. Complexity and catalytic efficiency of hepatitis C virus (HCV) NS3 and NS4A protease quasispecies influence responsiveness to treatment with pegylated interferon plus ribavirin in HCV/HIV-coinfected patients. J Virol 2011; 85: 5961-9.
32. Fernandez J, Taylor D, Morhardt DR, et al. Long-term persistence of infection in chimpanzees inoculated with an infectious hepatitis C virus clone is associated with a decrease in the viral amino acid substitution rate and low levels of heterogeneity. J Virol 2004; 78: 9782-9.
33. Kuntzen T, Timm J, Berical A, et al. Viral sequence evolution in acute hepatitis C virus infection. J Virol 2007; 81: 11658-68.
34. Wagner A. Robustness and evolvability: a paradox resolved. Proc Biol Sci 2008; 275: 91-100.
35. Saakian DB, Hu CK. Exact solution of the Eigen model with general fitness functions and degradation rates. Proc Natl Acad Sci U S A 2006; 103: 4935-9.
36. Day CL, Lauer GM, Robbins GK, et al. Broad specificity of virus-specific CD4 + T-helper-cell responses in resolved hepatitis C virus infection. J Virol 2002; 76: 12584-95.
37. Grakoui A, Shoukry NH, Woollard DJ, et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 2003; 302: 659-62.
38. Missale G, Bertoni R, Lamonaca V, et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 1996; 98: 706-14.
39. Sadegh-Nasseri S, Dalai SK, Korb Ferris LC, Mirshahidi S. Suboptimal engagement of the T-cell receptor by a variety of peptide-MHC ligands triggers T-cell anergy. Immunology 2010; 129: 1-7.
40. Puig M, Mihalik K, Tilton JC, et al. CD4 + immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus. Hepatology 2006; 44: 736-45.
41. Brooks DG, Teyton L, Oldstone MB, McGavern DB. Intrinsic functional dysregulation of CD4 T cells occurs rapidly following persistent viral infection. J Virol 2005; 79: 10514-27.
42. Brooks DG, McGavern DB, Oldstone MB. Reprogramming of antiviral T cells prevents inactivation and restores T cell activity during persistent viral infection. J Clin Invest 2006; 116: 1675-85.
43. Farci P. New insights into the HCV quasispecies and compartmentalization. Semin Liver Dis 2011; 31: 356-74.
44. Pawlotsky JM, Hepatitis C. virus population dynamics during infection. Curr Top Microbiol Immunol 2006; 299: 261-84.
45. Weiner A, Erickson AL, Kansopon J, et al. Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. Proc Natl Acad Sci U S A 1995; 92: 2755-9.
46. Erickson AL, Kimura Y, Igarashi S, et al. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 2001; 15: 883-95.
47. Thimme R, Bukh J, Spangenberg HC, et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci U S A 2002; 99: 15661-8.
48. Kuiken C, Combet C, Bukh J, et al. A comprehensive system for consistent numbering of HCV sequences, proteins and epitopes. Hepatology 2006; 44: 1355-61.